Nivolumab

CHEBI:CHEBI_747814

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

pharm_class_epc
Lymphocyte Activation Gene-3 Blocker [EPC]
pharm_class
Lymphocyte Activation Gene-3 Antagonists [MoA]
pharm_class_moa
Lymphocyte Activation Gene-3 Antagonists [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
generic_name
nivolumab and relatlimab-rmbw
rxcui
2569081
product_type
BULK INGREDIENT
listing_expiration_date
20241231
dosage_form
LIQUID
active_ingredient_strength
12 mg/mL
route
INTRAVENOUS
marketing_start_date
20210830
marketing_category
BULK INGREDIENT
package_marketing_start_date
04-APR-19
product_ndc
0003-3756
labeler_name
Lotte Biologics USA, LLC
spl_id
a09ce754-0cbe-4895-b143-290d292733f5
active_ingredient_name
RELATLIMAB
package_ndc
0003-3756-14
package_description
1 VIAL, SINGLE-DOSE in 1 CARTON (0003-3756-14) / 12 mL in 1 VIAL, SINGLE-DOSE
manufacturer_name
E.R. Squibb & Sons, L.L.C.
brand_name
OPDIVO
brand_name_base
OPDIVO
application_number
BLA125554
unii
AF75XOF6W3
spl_set_id
f570b9c4-6846-4de2-abfa-4d0a4ae4e394
nui
N0000194002